Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity.
The aim of this study was to evaluate the role of osteopontin (OPN) in cyclosporine (CsA) nephrotoxicity of the human kidney. Renal biopsy samples obtained before and after 1-2 years of CsA treatment were evaluated in 18 children (2.2-13.0 years, 14 males, 4 females) diagnosed with minimal change nephrotic syndrome. The changes in tubular OPN expression between pre- and post-treatment samples were correlated with interstitial macrophage infiltration, transforming growth factor-beta (TGF-beta) expression, interstitial fibrosis, and microvascular density. OPN, TGF-beta, CD68, and CD34 positivity were quantitatively assessed by immunohistochemical staining. Light microscopy showed that interstitial fibrosis developed in two-thirds of patients after CsA treatment. However, CD68-positive macrophages infiltrated minimally in fibrotic areas and were found in only one-third of patients. OPN expression was significantly increased in the glomerular mesangium (P=0.001) and tubules (P=0.025) after CsA treatment, whereas the number of CD34-positive peritubular capillaries decreased (P=0.022). An inverse relationship was observed between tubular OPN expression and microvascular density (r=-0.644). However, tubular OPN expression was not related to proteinuria, interstitial fibrosis, or interstitial or tubular TGF-beta expression. This study indicates that increased OPN expression may be related to microvascular injury in human CsA nephrotoxicity. It also shows that OPN expression may be used as an early but non-specific marker of CsA toxicity before the manifestation of interstitial fibrosis.
Lim
Beom Jin
BJ
Department of Pathology, College of Medicine, Yonsei University, Seoul, Korea.
Kim
Pyung Kil
PK
Hong
Soon Won
SW
Jeong
Hyeon Joo
HJ
D015415:Biomarkers; D001706:Biopsy; D002196:Capillaries / Q000473:pathology; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007678:Kidney Glomerulus / Q000098:blood supply / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000378:metabolism*; D053495:Osteopontin; D012795:Sialoglycoproteins / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000378:metabolism
D015415:Biomarkers; D007166:Immunosuppressive Agents; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D016212:Transforming Growth Factor beta; D053495:Osteopontin; D016572:Cyclosporine